Delivery Order SPE2DB22D2211-SPE2DB25FSBHR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for RINVOQ ER 15 mg tablets (30-unit bottles) under a firm fixed-price contract valued at $10,362.56. This is a non-set-aside competitive award with an ultimate completion date of July 30, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,138.54 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vehicle running through December 2026 that provides comprehensive pharmaceutical and...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) valued at $9,780.29 under a firm fixed-price contract type. The award, made on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,015.55 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit of use packaging) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price, non-set-aside delivery order was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's larger indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,172.92 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 20, 2025, with ultimate completion by August 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $39,043.38 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 21, 2025, with a completion date of August 22, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which carries a $999,999,999.00 potential value through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. The contract is valued at $11,191.56 with a firm fixed price structure and carries an ultimate completion date of August 22, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive...
- The Defense Logistics Agency awarded a $26,705.50 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed price structure. This non-competitive delivery order was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-count units) valued at $7,265.22 under a firm fixed-price contract type. The award was made on July 23, 2025, with an ultimate completion date of July 24, 2025, and represents a non-competitive, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSBHRDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,525.88 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. This delivery order exemplifies the operational scope of AmerisourceBergen Drug Corp's federal pharmaceutical supply mission, providing brand-name specialty medications to support military and veteran healthcare systems. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the company's role in delivering critical therapeutic medications across multiple therapeutic domains. The award demonstrates DLA's continued reliance on AmerisourceBergen Drug Corp's distribution capabilities through its prime vendor program, which enables flexible procurement of pharmaceutical products to meet evolving military healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $33.5k | 7/22/25 |